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Abstract-The purpose of this opinion is to present a case for targeting sphingosine kinase 2 
(SK2) in autoimmune/inflammatory disease.  Data obtained using Sphk2-/- mice suggests 
that SK2 is an anti-inflammatory enzyme, although this might be misleading because of a 
compensatory increase in expression of a second isoform, sphingosine kinase 1 (SK1), 
which functions as a pro-inflammatory enzyme.  SK2 is involved in regulating interleukin-
12/interferon-J and histone deacetylase-1/2 signalling and potentially retinoid related 
orphan receptor-Jt stability linked with Th17 cell polarisation.  Therefore, there is a need 
to develop highly potent SK2 inhibitors with selectivity over SK1 to clearly define the role 
of SK2 in autoimmune/inflammatory disease.  Structural determinants of SK2 relative to 
SK1 will enable design of selective SK2 inhibitors. 
 
Sphingosine 1-phosphate Signalling 
The bioactive lipid, sphingosine 1-phosphate (S1P) is formed by the phosphorylation of 
sphingosine and this reaction is catalysed by two isoforms of sphingosine kinase, termed SK1 
and SK2.  These enzymes are encoded by different genes and are localised in distinct sub-
cellular compartments.  The enzymes also exhibit distinct biochemical properties and inhibitor 
sensitivities [1].  S1P is degraded by S1P lyase to produce (E)-2-hexadecenal and 
phosphoethanolamine and is dephosphorylated by S1P phosphatase to reform sphingosine [1].  
S1P is released from cells using specific transporters (e.g. Spns2) (see Glossary) in the plasma 
membrane and binds to a family of G protein-coupled receptors (GPCR), the S1P receptors 
(S1P1-S1P5) [2, 3] on cells to induce biological responses. Intracellular S1P formed by SK2 can 
bind to various targets, such as histone deacetylase 1/2 (HDAC-1/2) [4], human telomerase 
reverse transcriptase (hTERT) [5] and prohibitin 2 [6], thereby linking the enzyme with 
epigenetic regulation, aging and mitochondrial respiratory complex assembly respectively.   
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SK1 and SK2 exhibit some redundancy in function, as evident from studies in Sphk1
-/- 
or 
Sphk2
-/- 
mice, which are phenotypically healthy while deletion of both genes is embryonic lethal 
[7]. These enzymes appear to regulate discrete sub-cellular pools of intracellular S1P that govern 
both overlapping and/or distinct biology.  The importance of SK2 is evinced by the fact that it 
has a critical role in governing the clinical efficacy of FTY720 (Gilenya®), which is 
phosphorylated by SK2 to produce FTY720-phosphate and which functions to modulate S1P 
receptors.   SK1 and SK2 are regulated by post-translational modification and interact with 
specific proteins and lipids (for review see [8]).  For instance, both enzymes are phosphorylated 
by extracellular signal-regulated kinase (ERK) and this promotes translocation of SK1 from the 
cytoplasm to the plasma-membrane, where it can access sphingosine [9, 10]. In contrast, SK2 is 
localised to the endoplasmic reticulum, nucleus or is associated with mitochondria [11].  In 
addition, SK2 contains nuclear localisation and export sequences and when phosphorylated by 
protein kinase D is exported from the nucleus to the cytoplasm [12].  The aim of this opinion is 
to evaluate the role of SK2 in autoimmune/inflammatory disease.  This is both necessary and 
timely because data obtained using Spk2
-/- 
mice suggest an anti-inflammatory role for this 
enzyme, while SK2 inhibitors indicate a pro-inflammatory role.  It is important to appraise this 
issue so that the full potential of SK2 as a target for therapeutic intervention in 
autoimmune/inflammatory disease can be evaluated.  We have therefore discussed the data 
obtained with Sphk2
-/-
 mice, assessed the role of SK2 in IL-12 signalling and Th17 polarisation 
that contribute to autoimmune disease and have provided information on how inhibitor 
selectivity for SK2 over SK1 inhibitors can be achieved.  This is necessary to distinguish SK2 
function from that of SK1 and to provide impetus for the use of SK2 inhibitors in 
autoimmune/inflammatory disease. 
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Consideration of evidence obtained with Sphk2-/- mice 
Data obtained using Sphk2
-/-
 mice suggest that SK2 might function as an anti-
inflammatory enzyme.  In our opinion, the Sphk2
-/-
 model is not entirely informative as genetic 
knockout or RNAi knockdown of SK2 in cells can lead to increased expression of SK1 [13-15].  
In addition, Sphk2
-/-
 mice exhibit higher S1P levels in whole blood, serum, lymphatic fluid and 
mesenteric lymph nodes and it has been suggested that this is due to a compensatory increase in 
SK1 expression [16]. Other studies have shown no change in SK1 mRNA in brain, heart and 
lung, liver, spleen and kidney in Sphk2
-/-
 mice, although protein expression was not investigated 
[7]. Clearly, further studies are required to investigate the inter-relationship between SK2 and 
SK1.  Nevertheless, the pro-inflammatory effects observed in Sphk2
-/-
 mice might be attributable 
to increased SK1 expression.  Indeed, Sphk1
-/-
 mice are protected from ulcerative colitis, 
indicating that SK1 functions as a pro-inflammatory enzyme in this disease [17].  Such an 
increase in SK1 expression levels in the Sphk2
-/-
 mice is not recapitulated with selective SK2 
inhibitors.  These data indicate that there is a fundamental difference in how chronic loss of SK2 
protein through genetic knockout/knockdown versus inhibition of SK2 activity with small 
molecules can affect SK1 expression.  In our opinion, this has hindered evaluation as to whether 
SK2 is, in fact, a pro-inflammatory enzyme and therefore, a viable target for intervention in 
autoimmune/inflammatory disease.  In addition, Kharel et al. [18] observed that the treatment of 
mice with the SK2 inhibitor, SRL080811 increased blood S1P levels.  This contrasts with the 
effect of SK2 inhibitor, ABC294640 which lowers S1P levels [19].  Since SRL080811 
recapitulated the effect of Sphk2
-/-
 mice, the authors have suggested that SK2 might exhibit 
additional activities in regulating S1P uptake into cells.  However, the effects of SRL080811 and 
the Sphk2 knockout might represent mutually exclusive events.   
5

Information from the Sphk2
-/- 
mice needs to be very carefully de-convoluted.  A couple 
of examples are given here.  First, Samy et al. [20] demonstrated that Sphk2
-/-
 CD4+ cells exhibit 
a hyper-activated phenotype with significantly enhanced proliferation and cytokine secretion 
(IFN-J) in response to IL-2, as well as reduced sensitivity to T(reg)-mediated suppression in 
vitro.  However, the authors suggested that these effects are independent of S1P and S1P 
receptors.  The former is based on the finding that intracellular S1P levels are not altered in 
Sphk2
-/-
 CD4
+
 cells.  This is, in fact, consistent with increased SK1 expression rebalancing S1P 
levels and/or possible non-catalytic functions of SK2 affecting CD4
+
 cells; the latter which 
would not be recapitulated by SK2 inhibitors.  Therefore, the observed effects of Sphk2 
knockout on IL-2 signalling in these cells might be mediated by SK1. 
Second, Bajwa et al. [21] demonstrated that Sphk2
-/-
 mice do not develop kidney fibrosis 
in response to injury induced by folic acid and that this is associated with increased levels of the 
pro-inflammatory mediator, IFN-J, which is anti-fibrotic. Thus, SK2 is suggested to be a 
negative regulator of IFN-J.  However, an earlier publication by this group demonstrated that 
SK1 mRNA transcript levels are increased in SK2 null mice in kidneys subjected to 
ischaemic/reperfusion injury [22].  Moreover, overexpression of SK1 increases IL-12 formation 
from dendritic cells and RNAi knockdown in these cells prevents IFN-J formation from Th1 
cells [23].  Therefore, the effects on IFN-J formation in Sphk2-/- mice might be attributable to 
increased expression of SK1.  A significant finding in the study by Bajwa et al. [21] was the 
demonstration that the number of infiltrating CD3+ T cells, CD11b+ neutrophils and 
macrophages in the fibrotic kidney from Sphk2
-/-
 mice are considerably reduced compared with 
WT mice.  This cannot be explained by an increase in SK1 expression in Sphk2
-/-
 mice, as this 
would potentially increase inflammatory cell infiltration in the kidney.  Therefore, the anti-
inflammatory profile is likely attributable to the loss of SK2 and this supports our proposal that 
SK2 is, in fact, a pro-inflammatory enzyme that can affect T-cell dynamics.  In addition, folic 
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acid increased mRNA expression levels of innate pro-inflammatory mediators e.g. CXCL1 and 
CXCL2 in WT and Sphk1
-/-
 mice but not Sphk2
-/-
 mice.   
There is more direct evidence obtained using Sphk2-/- mice that SK2 can function in a 
pro-inflammatory context as these mice are protected against experimental auto-immune 
encephalomyelitis (EAE) [24], a disease model of Multiple Sclerosis (MS).  In addition, we 
have shown that the PM potent SK2 inhibitor, (R)-FTY720 methyl ether (ROMe) prevents 
inflammatory cell infiltration into the spinal cord and recapitulates the Sphk2 knockout in 
reducing disease progression in the EAE model [25]. In addition, the SK2 inhibitor, Yeliva
®
 
(ABC294640) exhibits anti-inflammatory activity in rodent models of Inflammatory Bowel 
Disease (IBD) [26-28] and arthritis [29].  Finally, hydroxy-based SK1/SK2 inhibitors have also 
been shown to exert anti-inflammatory activity in colitis in mice [30].  Therefore, there is some 
preliminary evidence that SK2 inhibitors might be exploited for the treatment of auto-
immune/inflammatory disease. 
 
Rationale for targeting sphingosine kinase 2 
SK1 is involved in so-called inside-out signalling, where S1P formed by SK1 is 
released from cells through transporters to act on S1P receptors in an autocrine manner [31]. 
Evidence that SK2 can perform a similar function is scant.  However, SK2 catalyses the 
phosphorylation of FTY720, and the phosphorylated FTY720 can be released from cells to 
functionally antagonise S1P1 on T-cells [32]. Significantly, this underlies the mechanism by 
which FTY720 phosphate modulates T-cell polarisation and trafficking and which is clinically 
effective in MS patients. Therefore, SK2 can indirectly regulate S1P receptors and this is 
consistent with the partial redundancy of function seen in Sphk1
-/- 
or Sphk2
-/- 
mice.  It follows 
that the selective inhibition of SK2 activity has the potential to block localized S1P synthesis, 
thereby reducing availability of S1P at S1P receptors and at intracellular targets (e.g. HDAC-1/2) 
7

involved in inflammatory disease-forming mechanisms (Figure. 1). This is a plausible 
therapeutic approach as S1P is involved in IBD, Psoriasis (Ps) and MS [33, 34].   
 
Target validation of SK2 in Th1 driven auto-immune disease 
Is there evidence that SK2 can function in molecular signalling pathways that affect T-
cell sub-sets that drive auto-immune disease?  In this regard, the IL12E1 receptor, which binds 
IL-12, has been shown to form a complex with SK2 [35].  Moreover, over-expression of 
dominant negative or wild-type SK2 reduce and enhance IL-12-stimulated IFN-J formation 
respectively in T-cells (Figure 2) [35]. Therefore, it would be of considerable interest to evaluate 
the effect of more potent SK2 inhibitors with selectivity over SK1 and in combination with for 
example, IL-12 antibodies to establish whether there is improved efficacy in Th1-mediated 
disease models compared with either agent alone (Figure 3).  In theory, decreasing IL-12 levels 
with antibody should reduce the extent to which SK2 can be activated by IL-12 and this might 
enable SK2 inhibitors to more effectively block IL-12-stimulated IFN-J production.  
 
SK2 and potential link with STAT3, IL-6 and IL-17 
SK2 might also play a significant role in Th17 biology.  This is based on the fact that the 
IL-23 receptor dimerizes with IL12E1 receptor required for IL-23-stimulated IL-17 formation 
[36].  Indeed, there is substantial evidence supporting a role for S1P in promoting Th17 
polarisation [37].  For instance, S1P increases phosphorylated Signal Transducer Activator of 
Transcription 3 (STAT3) levels and IL-6 formation [38]; the latter is a major stimulator of Th17 
polarisation.  In addition, STAT3 increases ROR-Jt expression [39] and STAT3 or ROR-Jt 
knockout reduces Th17 polarisation [39, 40]. Based on these findings, it is possible that S1P 
stimulates Th17 polarisation via a ROR-Jt-dependent mechanism.  Therefore, one could evaluate 
the effect of more potent SK2 inhibitors with selectivity over SK1 in combination with IL-17 
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antibodies to establish whether there is improved efficacy in Th17-mediated disease models 
compared with either agent alone (Figure 3).  SK2 inhibitors are expected to reduce IL-17 
formation, thereby increasing the capacity for IL-17 antibody (at a given dose) to neutralise the 
lower amounts of IL-17 produced. 
 
SK2 and potential link with T(reg) and auto-immune disease 
S1P also inhibits T(reg) (Foxp3+) [41] and this involves an S1P1-dependent negative 
regulation of TGFE signalling that requires SK activity and is blocked by SK inhibitors.  Both 
SK1 and SK2 in T(reg) are up-regulated by TGFE>@.  However, SK1 normally promotes 
TGFE signalling.   For instance, SK1 is involved in TGFE-stimulated fibroblast transformation 
mediated by S1P2/3 [42].  Thus, TGFE might alternatively use SK2 to increase S1P levels, which 
via inside-out signalling acts on S1P1, thereby inhibiting TGFE-induced T(reg) formation in a 
negative feedback manner.  Thus, SK2 inhibitors might enhance T(reg) function to suppress 
autoimmune disease and this could be potentially augmented by combination with anti-IL-12 and 
IL-17 antibodies. 
 
SK2 and potential link with ROR-Jt 
HDAC-1 catalyses de-acetylation of ROR-Jt [43] and reduces its stability in cells. 
Indeed, HDAC1 inhibitors maintain acetylated ROR-Jt to increase Th17 polarisation [43].  
Significantly, S1P formed by SK2 inhibits HDAC1 [44].  Thus, SK2 inhibitors, in reducing S1P 
levels might reactivate HDAC1 and promote ROR-Jt deacetylation and degradation, thereby 
limiting Th17 polarisation.  This also provides a rationale for evaluating whether combined 
treatment with SK2 inhibitors and ROR-Jt inverse agonists improves efficacy in Th17-mediated 
disease models (Figure. 3).  In reducing ROR-Jt stability, SK2 inhibitors might enable inverse 
agonists to decrease ROR-Jt activity to below threshold levels required to promote IL-17 
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formation.  Such threshold levels are likely to exist as weak strength T-cell activation is 
sufficient to stimulate IL-17 formation [45].   
Potential advantages of targeting SK2 over S1P receptors in auto-immune disease 
A major effort in tackling auto-immune disease involves the use of S1P1 modulators, 
such as Gilenya
®
 and ozanimod, which initially agonise S1P1 and then promote proteasomal 
degradation of the receptor (functional antagonism) to prevent T-cell egress and therefore limit 
deleterious effects of autoreactive T-cells on the central nervous system (CNS).  Side effects of 
certain S1P receptor modulators include transient bradycardia, QT prolongation, macular edema, 
early reduced FEV, headache, anaemia, higher transaminase levels (liver), nasopharyngitis, 
urinary tract and viral infection.  SK2 inhibitors are not reliant on S1P1/3 agonism thereby 
potentially minimising some of these side effects. Moreover, Yeliva
®
 causes only a modest 
decrease in lymphocyte count. This is important, as a severe decrease in lymphocytes number 
may make patients susceptible to certain infections including rare, but fatal progressive 
multifocal leukoencephalopathy (PML). Indeed, lymphopenia is linked with reactivation of 
the JC virus, which causes PML [46]. The modest effect of Yeliva
®
 on lymphocyte recirculation 
is supported by a partial or no effect on lymphopenia in Sphk2
-/-
 mice [24, 47].  Therefore, 
patients treated with SK2 inhibitors might have reduced risk from infection compared with the 
use of S1P1 functional antagonists.  
 
Selectivity of SK2 inhibitors over SK1  
SK2-selective inhibitors reported to date include compounds 15 (Figure. 4, [26, 48-50]). 
Of these, Yeliva
®
 (1) is the most advanced and is currently in Phase 1/2 clinical trials for 
oncological indications. However, currently available SK2 inhibitors exhibit modest potency 
and/or selectivity over SK1 and, in some cases, modulate other targets. Thus, Yeliva
®
 exhibits 
SK2-inhibitory potency in the micromolar range, inhibits dihydroceramide desaturase and 
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induces proteasomal degradation of SK1 in cancer cells [51, 52]. A key consideration, then, is 
the feasibility of developing compounds that combine high potency with high selectivity to 
facilitate exploration of the full potential of SK2 as a pharmacological target for clinical 
intervention. 
Currently no SK2 crystal structures are available, but sequence comparison reveals strong 
homology to SK1, for which co-crystal structures with sphingosine (Sph) and with three Sph-
competitive inhibitors (68, Figure 4) have recently been solved [53-55].  The enzyme has a 
bidomain structure with a Sph-binding C-terminal domain (CTD) and an ATP-binding N-
terminal domain (Figure 5A/B). The CTD adopts a two-layer ȕ-sandwich with three lipid 
binding loops (LBL-1 to LBL-3) folding across one face to generate the Sph-binding cavity, 
termed the J-channel. A fourth inter-strand loop (the R-loop) packs on the opposite face of the 
CTD ȕ-sandwich and fulfills a regulatory role. This loop, which is much extended in SK2 and 
hosts the phosphorylation-dependent nuclear export signal sequence, constitutes one of the key 
differences between SK2 and SK1. Of the three lipid binding loops, LBL-1 consists of two 
reverse-paired helices (Į7/Į8) and may gate access to the J-channel by a hinged motion [56]. 
Residues in LBL-1 and LBL-2 contribute to the contact surface for the polar head group of the 
lipid and central region. LBL-3, which contains an additional helix (Į9) running antiparallel 
along Į8, encloses much of the lipid tail.  
Of the ca. 20 residues contributing to the ligand contact surface of the J-channel, SK2 
differs from SK1 in only three; these are Ile174, Met272 and Phe288 of SK1, corresponding 
respectively to Val304, Leu517 and Cys533 in SK2. Ile174 and Met272 contribute to the stem of 
the J-channel. In the SK1 co-crystal structure with PF-543 (8) (Figure 5C), these residues flank 
the inhibitors p-xylylene subunit; their replacement by Val and Leu may result in some re-
contouring of SK2 J-channel surface in this region. Phe288 plugs the toe of the SK1 J-channel; 
the cognate residue (Cys533) in SK2 is likely to result in a longer J-channel. However, 
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homology modelling suggests that isoform differences in non-contact residues may subtly adjust 
packing of LBLs and potentially impact on the conserved heel region of the J-channel, leading to 
some compaction in SK2 (Figure 5D).  
Another non-contact residue difference that may have bearing on development of SK2-
selective inhibitors is the substitution of Ala339 in SK1 by Thr584 in SK2. This residue lies 
proximal to a conserved aspartate (Asp178 in SK1) that engages the polar head group of Sph and 
inhibitors such as PF-543. Homology models indicate that presentation of the cognate aspartate 
(Asp308) in SK2 may be rotationally constrained by a hydrogen bond to Thr584 (Figure 5E). 
This, in turn, may impact on the optimal binding position of a basic centre within a ligand head 
group. In the case of the hydroxymethylpyrrolidine subunit of PF-543, this would suggest a 
preference for a slightly more deeply seated ammonium centre when bound to SK2. The 
pronounced SK1-over-SK2 inhibitory selectivity of PF-543 may then result from a tendency for 
a modest backward shunt of the ligand tail to sub-optimally compress the sulfonylmethylene 
linker in the heel region of the J-channel, which we suggest is tighter in SK2 than SK1 due to 
compaction of LBL-3.  Together these considerations suggest a strategy for the design of 
improved SK2 inhibitors by optimizing the ligand tail with softened steric demand in the heel 
and increased steric demand in the toe relative to SK1-selective inhibitors. Combining such a tail 
with a head group that doubly engages Asp308 (via OD1/OD2 oxygen centres) and spacer 
subunits of optimal length to bridge between the tail and head group may provide access to 
potent SK2 inhibitors with enhanced selectivity over SK1. 
Finally, given the flap-like structure of the lipid binding loops, we should also consider 
protein flexibility and whether tunneling of inhibitor tail subunits might be possible either 
between LBL-1/3 or between LBL-2/3. Thus, Schnute et al. [50] have recently disclosed Pfizer-
27c (5) as a potent SK2 inhibitor with modest selectivity over SK1. These authors note that 
direct mapping of Pfizer-27c onto SK1-bound PF-543 reveals that the terminal oxadiazole ring is 
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too large for accommodation in the heel of the J-channel, and thus it is proposed that phenoxy 
ring is rotated to present the oxazdiazole between helices Į8 and Į9 of LBL-1 and LBL-3. 
Validation of such a binding mode might open alternative strategies for optimizing SK2-
selective inhibitors to take advantage of isoform differences in residues not directly contributing 
to the J-channel. 
 
Concluding Remarks 
One has to carefully de-convolute data obtained with Sphk2
-/- 
mice to enable better definition of 
the role of SK2 in autoimmune/inflammatory disease and to provide a rationale for targeting this 
enzyme.  This also raises a number of questions and areas for future research (see Outstanding 
Questions). Moreover, more highly potent and selective SK2 isoform inhibitors are needed to 
validate the role of SK2 and to allow optimisation and translation to the clinic.  Such inhibitors 
can be used to establish whether the regulation of IL-12-stimulated IFN-J formation by SK2 is 
major determinant in promoting autoimmune disease, using, for instance, the IL-10
-/- 
mouse 
model of Crohns disease.  Such inhibitors can also be used to assess whether they reduce 
HDAC-1 levels and block Th17 polarisation in, for instance, EAE with comparison with Sphk2
-/-
 
mice models. Therefore, further studies on the role of SK2 in autoimmune/inflammatory disease 
are required in the future. 
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Figure Legends 
Figure. 1 Effect of inhibiting SK2 on S1P-dependent autoimmune/inflammatory disease 
forming mechanisms.  The schematic shows that inhibiting SK2 activity can potentially reduce 
the availability of S1P at S1P receptors, which regulates Th17 polarisation.  In addition, S1P 
formed by SK2 can bind to intracellular targets such as HDAC-1/2, which can regulate ROR-Jt 
(a master transcriptional regulator of Th17 polarisation) stability and suggesting that SK2 
inhibitors might therefore reduce ROR-Jt levels. 
  
Figure. 2 Role of SK2 in regulating IL-12-dependent IFN-J from Th1 cells. The schematic 
shows that inhibiting SK2 might reduce signal transmission from the IL-12E1 receptor, which 
has been shown to form a complex with SK2.  Indeed, a dominant negative SK2 mutant has been 
shown to reduce IL-12-stimulated IFN-J formation. 
 
Figure. 3 Potential for combination approaches using SK2 inhibitors with IL-12/IL-17 
antibodies or ROR-Jt inverse agonists.  Possible strategies for use of potent SK2 inhibitors 
with selectivity over SK1 in combination with anti-IL-12 or anti-IL-17 antibodies or ROR-Jt 
inverse agonists to target Th1/Th17-mediated autoimmune/inflammatory disease. 
 
Figure. 4. Structure of representative SK inhibitors with inhibitory activity data. 
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Figure. 5. Key Figureure.  Structure of SK1 with SK2 homology annotations.  (A) The 
structure of SK1 with bound PF-543 (8) is shown (PDB: 4V24). The position of the ATP-
binding site is marked with ADP (pink surface), superimposed from the SK1 crystal structure 
(3VZD) with bound Mg-ADP. Three lipid binding loops (LBL-1 to LBL-3, colour coded as 
indicated in the ribbon key) pack to generate the Sph-binding J-channel (coloured mesh).  (B) As 
panel (A) but with 90° rotation about the horizontal axis to highlight regions of postulated 
compaction and potential tunneling relevant to the design of SK2 inhibitors.  (C) Detail of the 
SK1 J-channel surface (grey mesh) extracted from (A) and highlighting three isoform differences 
in surface-contributory residues; bound PF-543 (green stick) is visible within the surface.  (D) 
SK1 J-channel surface (grey mesh) with superimposed modelled SK2 J-channel surface 
(magenta), highlighting regions of postulated compression and expansion relative to SK1.  (E) 
SK1 J-channel surface (grey mesh) with bound PF-543 (green stick) rotated to view residues 
relevant to ligand head group engagement (SK1 Asp178 and Ala339, yellow stick); cognate SK2 
residues (Asp308 and Thr584, thin blue stick) are shown superimposed from a homology model, 
where Thr584 is predicted to engage and constrain presentation of Asp308 to impact on the 
optimal positioning of bound ligand. 
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